This study aimed to determine the effect of melatonin on thrombosis, sepsis, and mortality rate in adult patients with severe coronavirus infection (COVID-19).
Tags: COVID-19, Melatonin, Sepsis, Thrombosis
Reference: Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences.
Reference: Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, double-blind clinical trial
Background: Melatonin has been known as an anti-inflammatory agent and immune modulator that may address progressive pathophysiology of coronavirus disease 2019 (COVID-19).
Tags: Adjunctive therapy, Melatonin
Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.
Tags: COVID-19, Famotidine, Hydroxychloroquine
Reference: Efficacy of high dose vitamin C, melatonin and zinc in Iranian patients with acute respiratory syndrome due to Coronavirus infection: A pilot randomized trial.
INTRODUCTION: Our aim was to investigate the efficacy of vitamin C, melatonin, and zinc in patients with severe Covid-19.
SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure.
Reference: Famotidine use is not associated with 30-day mortality: A coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system
Previous reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation.1 , 2 In 1 of these studies the authors proposed that famotidine inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease, 3-chymotrypsin-like protease, that is essential for breakdown of the immature SARS-CoV-2 protein particles that contribute to the inflammatory response seen in some COVID-19–infected individuals,1 which in turn can lead to acute respiratory distress syndrome, multiorgan dysfunction, physiologic deterioration, and death.3 In a global pandemic with a lack of US Food and Drug Administration–approved targeted therapeutic agents, identification and repurposing of well-established drugs with a proven track record of safety, affordability, and widespread availability are necessary.4 The purpose of this study was to evaluate the reported protective effect of famotidine on mortality in hospitalized COVID-19 patients.
Khan MS, Khan MS, Debnath Cr et al. PMID: 33293006 PMCID: PMC7837160 DOI: 10.1016/j.arbres.2020.08.007 Abstract No abstract available Keywords: ivermectin Source: https://pubmed.ncbi.nlm.nih.gov/34629660/ Archive: https://archive.is/wip/67u8W
Respiratory distress requiring intubation is the most serious complication associated with coronavirus disease 2019 (COVID-19).
Introduction: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine. Methods: Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020.